|
|
|
Insider
Information: |
Papadopoulos Stelios |
Relationship: |
Director, 10% Owner |
City: |
Gaithersburg |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
4,592,750 |
|
Indirect Shares
|
4,643,486 |
|
|
Direct
Value |
$32,049,392 |
|
|
Indirect Value
|
$32,648,514 |
|
|
Total
Shares |
9,236,236 |
|
|
Total
Value |
$64,697,906 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
4
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
4
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
Percentage
Gain/Loss : |
0.0%
|
-56.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genvec Inc |
GNVC |
Director |
2003-08-21 |
305,840 |
|
0 |
Premium* |
|
Anadys Pharmaceuticals Inc |
ANDS |
Director |
2007-09-14 |
814,206 |
2004-03-25 |
1,995,374 |
Premium* |
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director |
2006-02-06 |
35,930 |
2006-02-06 |
0 |
Premium* |
|
Biogen Idec Inc |
BIIB |
Director |
2022-06-15 |
10,095 |
2022-06-15 |
28,206 |
Premium* |
|
Exelixis Inc |
EXEL |
Director |
2024-05-20 |
1,260,578 |
2017-09-22 |
0 |
Premium* |
|
Bg Medicine, Inc. |
BGMD |
Director |
2013-01-30 |
1,187,713 |
2011-02-09 |
0 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
|
2024-03-14 |
978,388 |
2014-12-12 |
0 |
Premium* |
|
Eucrates Biomedical Acquisition ... |
EUCR |
Director, 10% Owner |
|
0 |
2020-11-24 |
2,619,906 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
EXEL |
Exelixis Inc |
Director |
|
2021-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,424 |
1,304,551 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
Director |
|
2021-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,275 |
7,840 |
0 |
- |
|
EXEL |
Exelixis Inc |
Director |
|
2022-02-22 |
4 |
S |
$19.56 |
$1,653,113 |
D/D |
(84,515) |
1,220,036 |
0 |
% |
|
EXEL |
Exelixis Inc |
Director |
|
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
1,239,611 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
Director |
|
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,255 |
10,095 |
0 |
- |
|
RGLS |
Regulus Therapeutics Inc. |
Director |
|
2023-04-13 |
4 |
A |
$0.90 |
$200,000 |
D/D |
222,198 |
728,388 |
0 |
- |
|
EXEL |
Exelixis Inc |
Director |
|
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,718 |
1,260,329 |
0 |
- |
|
RGLS |
Regulus Therapeutics Inc. |
|
|
2024-03-14 |
4 |
A |
$1.60 |
$400,000 |
D/D |
250,000 |
978,388 |
0 |
- |
|
EXEL |
Exelixis Inc |
Director |
|
2024-05-20 |
4 |
OE |
$19.57 |
$228,695 |
D/D |
11,686 |
1,272,015 |
0 |
- |
|
EXEL |
Exelixis Inc |
Director |
|
2024-05-20 |
4 |
S |
$21.00 |
$240,177 |
D/D |
(11,437) |
1,260,578 |
0 |
% |
|
85 Records found
|
|
Page 4 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|